Association of FHR5 With Disease Severity in ANCA-Associated Vasculitis. [PDF]
Li YJ +7 more
europepmc +1 more source
Is ANCA-Associated Vasculitis Ready for Personalized Medicine? [PDF]
Popa CA, Walsh M.
europepmc +1 more source
Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe kidney involvement. [PDF]
Chaudhari N +6 more
europepmc +1 more source
Severe Pulmonary-Renal Syndrome Due to Hydralazine-Induced ANCA-Associated Vasculitis. [PDF]
Gbenle AO +4 more
europepmc +1 more source
Mechanisms, clinical manifestations and management of cardiovascular diseases in ANCA-associated vasculitis. [PDF]
Chiara E +5 more
europepmc +1 more source
BAFF and APRIL signaling in the B-cell lineage: implications for the pathogenesis of ANCA-associated vasculitis. [PDF]
Shimojima Y +5 more
europepmc +1 more source
ANCA-associated vasculitis: a phase-oriented therapeutic framework from immunopathology to precision treatment. [PDF]
Treppo E +5 more
europepmc +1 more source
Interstitial lung disease in ANCA-associated vasculitis: comment on the article by Chalkia et al. [PDF]
Iannone C +3 more
europepmc +1 more source
The risk of primary lung cancer in ANCA-associated vasculitis: systematic review and meta-analysis. [PDF]
Chaisrimaneepan N +4 more
europepmc +1 more source
Real-world efficacy and safety of avacopan in ANCA-associated vasculitis: a retrospective comparative study. [PDF]
Thiele F +7 more
europepmc +1 more source

